The Federal Reserve cut interest rates by 25 basis points at the conclusion of its two-day meeting on Wednesday, marking the central bank's third cut of the year. Fed ...

• The Federal Reserve cut interest rates Wednesday by a quarter point as expected, lowering borrowing costs for the third time this year. • Wall Street rallied after Fed Chair Jerome Powell ruled out ...

The Federal Reserve cut interest rates for a third time this year, but officials were divided over their next move. Jerome Powell, the central bank’s chair, said “we haven’t made any decision about ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

The Federal Reserve lowered its benchmark interest rate by a quarter percentage point Wednesday, in an effort to support a weakening job market. But stubborn inflation and delayed economic data ...

The Federal Reserve on Wednesday cut its influential interest rate for the third time this year, pointing to a job market that Chairman Jerome Powell said may be weaker than it appears. The cut of a ...

Thanks to its latest decision on Wednesday – its final one for 2025 – the Federal Reserve has now reduced its key overnight lending rate by 1.75 percentage points since it began its rate-cutting cycle ...

The Federal Reserve will announce whether to cut interest rates at its December meeting, capping off a turbulent year for the U.S. economy defined by fresh labor market headwinds and tariff-fueled ...

Abstract: Online collision-free trajectory generation within a shared workspace is fundamental for most multirobot applications. However, many widely-used methods based on model predictive control ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Concept code for predicting precipitation using model fields (temperature, geopotential, wind velocity, etc.) as predictors for sub-areas across the British Isle.